Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025
04 nov. 2024 06h55 HE
|
Profound Medical Corp.
– TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code reimbursement for TULSA to be effective...
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
16 oct. 2024 16h15 HE
|
Profound Medical Corp.
– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final...
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
18 juil. 2024 16h30 HE
|
Profound Medical Corp.
TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Prostate Health Market Surges Towards USD 83.8 Billion by 2034, Fueled by Advancements in Diagnostic and Treatment Technologies | TMR Report
08 juil. 2024 09h58 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research. Inc. , July 08, 2024 (GLOBE NEWSWIRE) -- The prostate health market (Markt für Prostatagesundheit) was projected to attain US$ 31.9...
Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders
19 déc. 2023 07h00 HE
|
Onconetix, Inc.
CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer,...
Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™
18 déc. 2023 07h00 HE
|
Onconetix, Inc.
CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced the acquisition of Proteomedix AG, a private, commercial-stage...
Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer
26 avr. 2023 15h44 HE
|
Blue Water Biotech, Inc.
CINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced the appointment of Jay...
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
20 avr. 2023 07h30 HE
|
Blue Water Vaccines Inc.
Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader Focus Company to Host a Conference...
Midwest Institute for Non-Surgical Therapy (MINT) Introduces New Therapy to Treat Men With Enlarged Prostates
21 oct. 2022 09h00 HE
|
The Midwest Institute for Nonsurgical Therapy
ST. LOUIS, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Midwest Institute for Non-surgical Therapy (MINT) has introduced a new therapy to treat men with benign prostatic hyperplasia (BPH). The condition, which...
Benign Prostatic Hyperplasic Devices Market Worth $3.46Bn by 2028 at 7.6% CAGR Lead by Urology Lasers Segment (Highest CAGR of 8.4%) Global Analysis by The Insight Partners
22 juil. 2022 08h26 HE
|
The Insight Partners
New York, July 22, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Benign Prostatic Hyperplasic Devices Market Forecast to 2028 - COVID-19 Impact and Global...